Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
July 13, 2023 08:00 ET
|
Incannex Healthcare
Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain...
Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
July 10, 2023 07:30 ET
|
Incannex Healthcare
Highlights: Incannex to redomicile to the United States via a Scheme of Arrangement pursuant to Australian lawA newly formed Delaware corporation (Incannex Healthcare Inc.) will become the ultimate...
Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’s Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA’)
July 06, 2023 08:42 ET
|
Incannex Healthcare
Highlights: Incannex has received approval from Bellberry Human Research Ethics Committee (‘HREC’) to commence the bioavailability/bioequivalence (‘BA/BE’) clinical trial to assess the...
Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
June 23, 2023 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, June 23, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing medicinal cannabinoid...
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
June 16, 2023 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board
May 30, 2023 08:00 ET
|
Incannex Healthcare
Highlights: Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.Dr. Bill Richards is among the world’s best known psychedelic researchers and practitioners. He has...
Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company
May 16, 2023 07:50 ET
|
Incannex Healthcare
MELBOURNE, Australia, May 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation which details...
Incannex enters a lease for first psychedelic-assisted psychotherapy clinic
May 05, 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, May 05, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a medicinal cannabinoid and psychedelic pharmaceutical...
Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A
May 03, 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data...
Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A
May 02, 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...